CLEC12A and acute myeloid leukemia: Combined targeting of CD33 and CLL-1 could offer a valuable strategy against heterogenous disease as both antigens are often upregulated on AML, although complete expression of either may not be complete across entire blast populations to enable monotherapy approaches.